- Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk AssessmentJohn Yates
Merck and Company, Inc, Upper Gwynedd, Pennsylvania, USA
Obstet Gynecol 103:440-6. 2004..The objective of this study was to evaluate the association between HT cessation and hip fracture risk...
- Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled studySusan Greenspan
Department of Medicine, University of Texas Southwestern Medical School, Dallas 75216, USA
Mayo Clin Proc 77:1044-52. 2002..CONCLUSION: In this 3-month study, the incidence of upper GI tract adverse events in patients treated with once-weekly alendronate, 70 mg, was comparable to that with placebo...
- Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort StudyMichael R McClung
Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA
J Clin Endocrinol Metab 89:4879-85. 2004..5, 10.3, and 8.9% of women taking placebo, 2.5 mg alendronate, or 5 mg alendronate daily, respectively. Therapy with alendronate is an effective and promising strategy for the prevention of postmenopausal osteoporosis...
- Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)Erland Erdmann
Medizinische Klinik III der Universität zu Köln Kerpener Str 62, D 50937 Koln, Germany
Diabetes Care 30:2773-8. 2007..We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure...